Patients with kidney disease who take calcium-based phosphate binders to lower their phosphorus levels may be at a 22% higher risk of death that those who take other non-calcium based treatments.
A new study by Canadian researchers has found a reduction in the risk of death among patients who took the non-calcium based treatments sevelamer and lanthanum.
John Schieszer has the story in today’s Medical Minute.
Next post in The Medical Minute
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.